---
canonical_name: Nicotinamide Riboside
alternate_names: NR, Niagen, Tru Niagen, Nicotinamide Riboside Chloride, Nicotinamide-β-Riboside
canonical_topic: Nicotinamide Riboside for Health & Longevity
short_topic_lc: nicotinamide_riboside
creation_date: 2026-0825-1128
creator_ai_fullname: Grok 4.5
---

# Nicotinamide Riboside for Health & Longevity
<section id="top" markdown="1"></section>  
Evidence Review created on 08/25/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Grok 4.5  

**Also known as:** NR, Niagen, Tru Niagen, Nicotinamide Riboside Chloride, Nicotinamide-β-Riboside  

<!-- Motivation written last, after all other sections, so it reflects the full scope of the review. -->

  
## Motivation

Nicotinamide riboside is a form of vitamin B3 sold as an oral dietary supplement. Cells convert it into a coenzyme used to turn food into energy and to support repair of genetic material. That coenzyme tends to decline with age, and mouse work on longevity-linked enzymes made the supplement a candidate for people trying to preserve metabolic and neurological function later in life.  

Interest rose after a distinct conversion route was mapped in yeast and human cells in the mid-2000s, then after commercial products reached the market in the 2010s. Human studies later showed that blood levels of the coenzyme can rise within weeks of oral use, which is the headline biochemical finding that motivates this review.  

This review examines the evidence that oral nicotinamide riboside has meaningful benefits for health- and longevity-oriented adults, the risks and interactions that accompany supplementation, and how protocols, sourcing, and monitoring look in the current literature.  

**[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)**  


  
## Recommended Reading

High-level expert and editorial overviews of nicotinamide riboside as an NAD+ (nicotinamide adenine dinucleotide, a coenzyme used in cellular energy and DNA-repair reactions) precursor.  

<!-- Search, 2026-08-25: WebSearch for nicotinamide riboside plus Rhonda Patrick/foundmyfitness, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension, Lifespan.io; pages loaded for foundmyfitness.com/episodes/nad-nr-nmn, peterattiamd.com/nad-for-health-and-longevity/ (premium), peterattiamd.com/nr-supplements-and-cancer/ (free NR article), hubermanlab.com/episode/dr-peter-attia-supplements-for-longevity-their-efficacy, lifeextension.com/wellness/supplements/nmn-vs-nr, lifespan.io/topic/nr-nicotinamide-riboside-benefits-side-effects/. Chris Kresser coverage was limited to brief mentions in broader aging interviews, not a dedicated overview. Excluded Grokipedia, Examine, ConsumerLab, systematic reviews, Wikipedia, forums, and mainstream media. -->

- [NAD+ in Aging: Role of Nicotinamide Riboside and Nicotinamide Mononucleotide](https://www.foundmyfitness.com/episodes/nad-nr-nmn) - Rhonda Patrick  

  Walks through human versus animal data on nicotinamide riboside and nicotinamide mononucleotide, including tissue-delivery limits and why NAD+ restoration is not yet a proven healthspan tool.  

- [NR supplements: wasted money may not be the only risk with these questionable "anti-aging" drugs](https://peterattiamd.com/nr-supplements-and-cancer/) - Peter Attia  

  Reviews mouse work linking nicotinamide riboside to faster tumor growth and treats NAD-precursor longevity claims as unproven.  

- [Dr. Peter Attia: Supplements for Longevity & Their Efficacy](https://www.hubermanlab.com/episode/dr-peter-attia-supplements-for-longevity-their-efficacy) - Andrew Huberman  

  Reviews nicotinamide riboside and related NAD precursors against human data, and separates biochemical or energy claims from lifespan evidence.  

- [NMN vs. NR: Everything You Need to Know About NAD Supplements](https://www.lifeextension.com/wellness/supplements/nmn-vs-nr) - Shayna Sandhaus  

  Compares nicotinamide riboside with nicotinamide mononucleotide as NAD precursors, including how each is used to support NAD+ and healthy aging.  

- [Nicotinamide Riboside (NR): Benefits and Side Effects](https://lifespan.io/topic/nr-nicotinamide-riboside-benefits-side-effects/) - Steve Hill  

  Summarizes what nicotinamide riboside is, how it feeds NAD+, and where human data stop short of energy and longevity marketing.  

Chris Kresser discusses nicotinamide riboside only in passing inside broader aging interviews, so no dedicated Kresser overview is listed.  


  
## Grokipedia

<!-- Search, 2026-08-25: d-browser to https://grokipedia.com/search?q=nicotinamide+riboside (64 results). Primary dedicated article: https://grokipedia.com/page/Nicotinamide_riboside. Related pages include Nicotinamide mononucleotide and nicotinamide riboside, and NAD precursors. -->

- [Nicotinamide riboside](https://grokipedia.com/page/Nicotinamide_riboside)  

  Encyclopedia overview of chemistry, the nicotinamide riboside kinase pathway (enzymes that convert the nucleoside toward NAD+), human NAD+ rises, and the 2024 peripheral artery disease walking trial.  


  
## Examine

<!-- Search, 2026-08-25: d-browser load of examine.com/search?q=nicotinamide+riboside hit a Vercel checkpoint; d-proxy-2 retrieved the same search and the dedicated page https://examine.com/supplements/nicotinamide-riboside/ (H1 Nicotinamide Riboside; Kamal Patel; updated 2025-08-28). Research-feed items exist but are not the primary page. -->

- [Nicotinamide Riboside](https://examine.com/supplements/nicotinamide-riboside/)  

  Dedicated Examine page on nicotinamide riboside as a vitamin B3 NAD+ precursor used for healthy aging and longevity, written by Kamal Patel.  


  
## ConsumerLab

<!-- Search, 2026-08-25: WebSearch site:consumerlab.com nicotinamide riboside Niagen; d-fetch of https://www.consumerlab.com/reviews/nmn-nadh-nicotinamide-riboside/nmn-nadh-nicotinamide-riboside/ confirmed the NAD Booster Supplements Review covering nicotinamide riboside, Tru Niagen, NMN, and NAD/NADH products. -->

- [NAD Booster Supplements Review (NAD+/NADH, Nicotinamide Riboside, and NMN)](https://www.consumerlab.com/reviews/nmn-nadh-nicotinamide-riboside/nmn-nadh-nicotinamide-riboside/)  

  Independent label testing of nicotinamide riboside products, notes on salt-form dosing and counterfeits, and a cautious evidence summary that includes cancer cautions.  


  
## Systematic Reviews

PubMed systematic reviews and meta-analyses that address nicotinamide riboside or NAD+ precursor supplementation, including claimed benefits and principal risks.  

<!-- Search, 2026-08-25: pubmed_search_articles for nicotinamide riboside AND (systematic review OR meta-analysis), plus nicotinamide riboside[tiab] AND review[pt]. Prioritized by recency, relevance to the intervention, and coverage of effect versus risk. -->

- [NAD⁺ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence](https://pubmed.ncbi.nlm.nih.gov/41655607/) - Gallagher & Emmanuel, 2026  

  Thirty-three human intervention studies: consistent NAD+ target engagement (the intended biochemical effect), generally good short-term tolerance, and heterogeneous, often null healthspan outcomes.  

- [The Effect of Nicotinamide Mononucleotide and Riboside on Skeletal Muscle Mass and Function: A Systematic Review and Meta-Analysis](https://pubmed.ncbi.nlm.nih.gov/40275690/) - Prokopidis et al., 2025  

  In adults over 60 years, neither precursor preserved muscle mass, grip, or gait; nicotinamide riboside helped 6-minute walk only in peripheral artery disease.  

- [Effects of NAD+ precursor supplementation on glucose and lipid metabolism in humans: a meta-analysis](https://pubmed.ncbi.nlm.nih.gov/35303905/) - Zhong et al., 2022  

  Pooled NAD+ precursors improved lipids but raised plasma glucose; subgroup effects were driven by nicotinic acid, not nicotinamide riboside.  

- [NAD+ therapy in age-related degenerative disorders: A benefit/risk analysis](https://pubmed.ncbi.nlm.nih.gov/31917996/) - Braidy & Liu, 2020  

  Systematic benefit-risk review of raising NAD+ in degenerative aging, including precursor routes and unresolved long-term safety questions.  

- [Supplementation with NAD+ Precursors for Treating Alzheimer's Disease: A Metabolic Approach](https://pubmed.ncbi.nlm.nih.gov/39422945/) - Alghamdi & Braidy, 2024  

  Systematic review of nicotinamide riboside and nicotinamide mononucleotide in Alzheimer models and early human biomarker work, still short of outcome trials.  


  
## Mechanism of Action

Nicotinamide riboside is a pyridine nucleoside form of vitamin B3. After oral intake, nicotinamide riboside kinases (NMRK1 and NMRK2, enzymes that attach a phosphate) convert it to nicotinamide mononucleotide, which is then adenylated to NAD+. This nicotinamide riboside kinase route bypasses nicotinamide phosphoribosyltransferase (NAMPT, the usual rate-limiting salvage enzyme). NAD+ shuttles electrons in mitochondria and is consumed by sirtuins (NAD-dependent deacetylases that remodel proteins) and poly(ADP-ribose) polymerases (PARPs, DNA-repair enzymes). CD38 (an NAD-cleaving hydrolase that rises with inflammation) is one proposed driver of age-related NAD+ loss.  

Two readings compete. One treats oral nicotinamide riboside as a way to restore sirtuin and mitochondrial programs that fade as NAD+ falls. The other notes that much of an oral dose is converted to nicotinamide in the gut and liver, so NAD+ rises are largest in blood cells and may not equal broad tissue repletion. Mouse flux work shows precursor cycling through intestine and microbiota rather than uniform delivery to muscle and brain.  

The parent nucleoside is short-lived in plasma, with an apparent half-life on the order of 2–3 hours, while whole-blood NAD+ stays elevated with daily dosing and can roughly double at 1,000 mg/day. Selectivity is that of a vitamin precursor, not a receptor ligand. Oral distribution favors liver and circulating cells; muscle metabolome (small-molecule profile) changes are documented, yet mitochondrial respiration often is not. Nicotinamide riboside is not a cytochrome P450 (CYP, a family of drug-metabolizing enzymes) substrate; downstream nicotinamide is methylated by nicotinamide N-methyltransferase (NNMT).  


  
## Historical Context & Evolution

Nicotinamide riboside was identified as a distinct NAD+ precursor in 2004, when Bieganowski and Brenner showed that yeast and human nicotinamide riboside kinases open a route to NAD+ that bypasses the classic nicotinic-acid Preiss-Handler pathway (the NAD+ route from niacin) ([Bieganowski & Brenner, 2004](https://pubmed.ncbi.nlm.nih.gov/15137942/)). It occurs in milk and yeast. Brenner's laboratory then showed oral bioavailability in mice and, in a 2016 human pharmacokinetic study, in people, with nicotinic acid adenine dinucleotide as a sensitive marker of NAD+ repletion ([Trammell et al., 2016](https://pubmed.ncbi.nlm.nih.gov/27721479/); coauthors included employees of ChromaDex, which sells Niagen). ChromaDex licensed the intellectual property as Niagen, obtained U.S. generally recognized as safe (GRAS) status, and supplied most later clinical material.  

Longevity interest grew from sirtuin biology and from mouse reports that NAD+ repletion improved stem-cell function and healthspan ([Zhang et al., 2016](https://pubmed.ncbi.nlm.nih.gov/27127236/); [Cantó et al., 2012](https://pubmed.ncbi.nlm.nih.gov/22682224/)). Those findings, not a deficiency disease, moved it from biochemistry into longevity use. Human trials from 2016 onward confirmed blood NAD+ rises without the flushing typical of nicotinic acid. Metabolic benefits seen in obese mice—insulin sensitivity, liver fat, endurance—largely failed insulin-clamp (a controlled infusion test of insulin sensitivity) and body-composition trials in insulin-resistant men ([Dollerup et al., 2018](https://pubmed.ncbi.nlm.nih.gov/29992272/)). The National Institute on Aging Interventions Testing Program found no lifespan extension in genetically heterogeneous mice at the dose tested ([Harrison et al., 2021](https://pubmed.ncbi.nlm.nih.gov/33788371/)). A 2023 review argued that several human papers overstated small effects ([Damgaard & Treebak, 2023](https://pubmed.ncbi.nlm.nih.gov/37478182/)). Company-funded research remains a large fraction of the evidence base, beside the biochemical data.  


  
## Expected Benefits

<!-- Benefit-profile search, 2026-08-25: PubMed nicotinamide riboside[ti] AND (randomized OR placebo OR trial) in humans (47 hits); systematic review/meta-analysis search; ClinicalTrials.gov interventionQuery nicotinamide riboside (123 studies); expert and Examine/ConsumerLab summaries. Outcomes covered: NAD+ engagement, blood pressure, PAD walking, Parkinson motor scores, COPD airway IL-8, circulating cytokines, muscle (null meta-analysis), insulin sensitivity (null clamps), cognition (null MCI), CKD VO2peak (null), ITP lifespan (null). -->

### High 🟩 🟩 🟩

No benefit reaches High: human trials are small and short, and they either raise unvalidated NAD+ metabolome markers or show a clinical endpoint in only a single adequately designed trial.  

### Medium 🟩 🟩

#### Walking Distance in Peripheral Artery Disease

In people with lower-extremity peripheral artery disease (PAD, atherosclerotic narrowing of leg arteries that limits walking), six months of oral nicotinamide riboside improved 6-minute walk distance versus placebo in a 90-person randomized trial. The proposed mechanism is higher NAD+ supporting calf-muscle mitochondria under ischemia. Resveratrol added no further walk benefit. The trial used a one-sided confidence interval (a statistical range that estimates the effect in one direction) and needs confirmation in a larger study now registered as NICE-PAD II.  

**Magnitude:** Between-group 6-minute walk +17.6 m at 6 months (nicotinamide riboside +7.0 m versus placebo −10.6 m); +31.0 m versus placebo among participants who took at least 75% of capsules ([McDermott et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38871717/)).  

#### Motor Scores in Parkinson Disease

Two small randomized trials in Parkinson disease (a neurodegenerative movement disorder) reported improved MDS-UPDRS (Movement Disorder Society Unified Parkinson's Disease Rating Scale, a standard motor and symptom score) during nicotinamide riboside. NADPARK showed a cerebral NAD+ rise on magnetic resonance spectroscopy and milder clinical change in those with brain NAD+ engagement. NR-SAFE used 3,000 mg/day and also improved scores, but the change tracked a shorter interval since the last levodopa dose. Both programs were phase I, short, and partly industry-supported.  

**Magnitude:** Direction: MDS-UPDRS improved over 4 weeks at 1,000–3,000 mg/day in two small trials; the literature reports no replicated, unconfounded effect size for disease modification ([Brakedal et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35235774/); [Berven et al., 2023](https://pubmed.ncbi.nlm.nih.gov/38016950/)).  

### Low 🟩

#### Systolic Blood Pressure ⚠️ Conflicted

A 6-week crossover reported a trend toward lower systolic blood pressure (the higher number in a blood-pressure pair), about 9 mmHg in an elevated-pressure subgroup. A later walking-exercise pilot showed no added daytime systolic drop versus exercise plus placebo. Net reading: the early vascular signal was not confirmed with exercise.  

**Magnitude:** Mean systolic change −3.9 mmHg versus placebo in the crossover (not significant after correction); exploratory −9 mmHg in the elevated/stage I subgroup; no added daytime systolic reduction versus exercise plus placebo in the later pilot ([Martens et al., 2018](https://pubmed.ncbi.nlm.nih.gov/29599478/); [Lin et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40770531/)).  

### Speculative 🟨

#### Circulating Inflammatory Cytokines

A 21-day crossover in aged men lowered circulating inflammatory cytokines, including IL-6 (interleukin-6, a systemic-inflammation marker), without changing muscle respiration. Basis is an unvalidated biomarker only ([Elhassan et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31412242/); [Damgaard & Treebak, 2023](https://pubmed.ncbi.nlm.nih.gov/37478182/)).  

#### Airway Inflammation in COPD

In stable COPD (chronic obstructive pulmonary disease), six weeks of nicotinamide riboside cut sputum IL-8 (interleukin-8, a neutrophil chemokine) without changing lung function or symptoms. Basis is a biomarker only ([Norheim et al., 2024](https://pubmed.ncbi.nlm.nih.gov/39548320/)).  

#### Human Lifespan or Healthspan Extension

Mouse stem-cell and healthspan reports sit against no lifespan effect in heterogeneous mice. No human trial has a lifespan endpoint. The basis is mechanistic and preclinical only ([Zhang et al., 2016](https://pubmed.ncbi.nlm.nih.gov/27127236/); [Harrison et al., 2021](https://pubmed.ncbi.nlm.nih.gov/33788371/)).  

#### Alzheimer-Related Neuronal Biomarkers

Nicotinamide riboside raised NAD+ in neuron-derived vesicles and lowered amyloid signals in older adults. A mild cognitive impairment trial found no cognitive gain. Basis is biomarker only ([Vreones et al., 2023](https://pubmed.ncbi.nlm.nih.gov/36515353/); [Orr et al., 2024](https://pubmed.ncbi.nlm.nih.gov/37994989/)).  

#### Skeletal Muscle Rejuvenation in Healthy Aging

Rodent NAD+ repletion restored muscle stem cells. Human studies show metabolome changes without consistent strength or respiration gains, and a 2025 meta-analysis was null in older adults ([Prokopidis et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40275690/)).  


  
## Benefit-Modifying Factors

- **Baseline NAD+:** In the Martens crossover, the NAD+ rise was larger when placebo-phase blood-cell NAD+ was lower, so people with a more depleted NAD+ pool may show greater biochemical engagement ([Martens et al., 2018](https://pubmed.ncbi.nlm.nih.gov/29599478/)).  

- **PAD versus healthy muscle:** Walk-distance gains appeared in PAD, not in healthy older adults or in pooled sarcopenia endpoints, so ischemic muscle may be a more responsive setting than intact muscle ([McDermott et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38871717/); [Prokopidis et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40275690/)).  

- **Age:** Most efficacy trials enrolled adults about 55–80 years, matching the age-related NAD+ decline rationale; metabolic clamps in younger-to-middle-aged obese men were null ([Dollerup et al., 2018](https://pubmed.ncbi.nlm.nih.gov/29992272/)).  

- **Sex:** Human dose–response is not well split by sex. An Interventions Testing Program lifespan study was null in both sexes; a COPD airway-transcriptome analysis noted sexual dimorphism without a dosing rule ([Harrison et al., 2021](https://pubmed.ncbi.nlm.nih.gov/33788371/)).  

- **NMRK1 / NNMT variants:** Activity of nicotinamide riboside kinases and of NNMT could, in principle, change conversion and methylation demand; no validated pharmacogenetic dosing algorithm exists.  

- **Pre-existing disease:** Parkinson disease, PAD, and COPD trials report tissue or clinical signals; hyperinsulinemic-euglycemic clamps in obese insulin-resistant men did not improve insulin sensitivity ([Dollerup et al., 2018](https://pubmed.ncbi.nlm.nih.gov/29992272/)).  


  
## Potential Risks & Side Effects

<!-- Side-effect search, 2026-08-25: PubMed safety, adverse events, homocysteine, cancer, metastasis; Conze 2019, Martens 2018, Dollerup 2018, Berven 2023 NR-SAFE, Norheim 2024, Gaare 2023, Maric 2023, Wang 2025 Apoe mouse atherosclerosis; EFSA novel-food nicotinamide riboside chloride opinions; Linus Pauling Institute niacin monograph; ConsumerLab NAD booster cautions. No dedicated drugs.com or Mayo Clinic nicotinamide-riboside drug monograph; safety taken from RCTs, EFSA, and supplement reviews. -->

### High 🟥 🟥 🟥

#### Mild Gastrointestinal Symptoms

Nausea, bloating, dyspepsia (indigestion), and loose stools are the adverse events most often listed as possibly related in randomized trials. They are typically mild, and several trials report similar gastrointestinal rates on placebo (about 10–14% in a COPD safety table). Dropouts attributed to nicotinamide riboside are uncommon. The signal is replicated as a mild, non-serious event class rather than a distinct toxic syndrome.  

**Magnitude:** Gastrointestinal events typically in the ~10–15% range and often similar to placebo in randomized trials at 300–2,000 mg/day; no moderate or severe events in a 3,000 mg/day, 4-week Parkinson disease safety trial ([Conze et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31278280/); [Norheim et al., 2024](https://pubmed.ncbi.nlm.nih.gov/39548320/); [Berven et al., 2023](https://pubmed.ncbi.nlm.nih.gov/38016950/)).  

### Medium 🟥 🟥

#### LDL Increase with Nicotinamide Riboside plus Pterostilbene

A nicotinamide riboside plus pterostilbene (a blueberry polyphenol) product raised low-density lipoprotein (LDL, the cholesterol fraction tied to atherosclerotic risk) in the double-dose arm of a 120-person trial. Nicotinamide riboside alone did not raise LDL in Conze. The lipid signal tracks the combination, not the nucleoside by itself.  

**Magnitude:** LDL about +3–3.5% versus placebo at the recommended nicotinamide riboside plus pterostilbene dose by day 60, with larger increases in the double-dose arm; nicotinamide riboside-only trials report no consistent LDL increase ([Dellinger et al., 2017](https://pubmed.ncbi.nlm.nih.gov/29184669/); [Conze et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31278280/)).  

### Low 🟥

#### Homocysteine Increase at High Dose

Nicotinamide from NAD+ turnover is methylated by NNMT and can raise homocysteine (a vascular-risk amino acid). At 1,000 mg/day, Conze found no rise. At 3,000 mg/day, NR-SAFE found +1.66 µmol/L with an intact methyl-donor pool; a Parkinson methylation study was unchanged.  

**Magnitude:** Homocysteine +1.66 ± 0.63 µmol/L at 3,000 mg/day over 4 weeks; no rise in an 8-week trial at up to 1,000 mg/day ([Berven et al., 2023](https://pubmed.ncbi.nlm.nih.gov/38016950/); [Conze et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31278280/); [Gaare et al., 2023](https://pubmed.ncbi.nlm.nih.gov/36936793/)).  

#### Flushing-Like Warmth and Headache

Unlike nicotinic acid, nicotinamide riboside does not reliably cause flushing. Isolated warmth, rash, or headache appear in trial adverse-event tables, including on placebo. Two of 12 participants reported feeling hot after 1,000 mg in an early pharmacokinetic series. These events have not clustered as a dose-limiting flush syndrome.  

**Magnitude:** 2 of 12 participants reported feeling hot after a 1,000 mg dose in an early pharmacokinetic series; no flush excess versus placebo in the 8-week NIAGEN trial ([Trammell et al., 2016](https://pubmed.ncbi.nlm.nih.gov/27721479/); [Martens et al., 2018](https://pubmed.ncbi.nlm.nih.gov/29599478/); [Conze et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31278280/)).  

### Speculative 🟨

#### Tumor Promotion or Metastasis

A mouse probe study linked nicotinamide riboside uptake to triple-negative breast-cancer growth and brain metastasis. Human incidence data are absent. The basis is preclinical only ([Maric et al., 2023](https://pubmed.ncbi.nlm.nih.gov/36371959/)).  

#### Atherosclerotic Plaque Promotion in Mice

Nicotinamide riboside increased plaque size and arterial inflammation in Apoe-knockout mice (animals engineered to develop atherosclerosis). Human plaque data are absent. The basis is preclinical only ([Wang et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40215896/)).  


  
## Risk-Modifying Factors

- **Dose:** Homocysteine and NAD-catabolite load scale with dose; 100–1,000 mg/day trials show little methylation disturbance, whereas 3,000 mg/day produced a small homocysteine rise ([Berven et al., 2023](https://pubmed.ncbi.nlm.nih.gov/38016950/)).  

- **NNMT / methyl-donor status:** Low folate, vitamin B12, or betaine, or high NNMT activity, could amplify homocysteine when nicotinamide clearance is high; not genetically actionable in clinic yet.  

- **Active malignancy:** Mouse metastasis work is the main modifier; several human protocols exclude active neoplastic disease within 1–2 years.  

- **Age and polypharmacy:** Older adults dominate trial safety databases; concomitant levodopa timing can confound Parkinson motor scores rather than prove toxicity.  

- **Sex:** No replicated sex-specific adverse-event pattern; trial samples are mixed and underpowered for interaction tests.  

- **Kidney function:** NAD catabolites including N-methyl-2-pyridone-5-carboxamide accumulate when eGFR (estimated glomerular filtration rate, a kidney-filtration estimate) is reduced; CKD (chronic kidney disease) trials exist but long-term metabolite safety is thin ([Ahmadi et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37159264/)).  


  
## Key Interactions & Contraindications

- **Other NAD precursors (nicotinamide, nicotinic acid, nicotinamide mononucleotide):** Caution. Additive NAD+ and nicotinamide load; high nicotinamide can inhibit sirtuins. Mitigation: avoid combining high doses of several vitamin B3 forms.  

- **Nicotinic acid (niacin) flush products:** Caution. Combined vitamin B3 load can add flushing, liver-enzyme strain, and nicotinamide that can inhibit sirtuins. Mitigation: do not combine high-dose niacin with nicotinamide riboside as one NAD protocol.  

- **Pterostilbene / resveratrol combinations (Elysium Basis-type products):** Monitor. LDL rose in a double-dose nicotinamide riboside plus pterostilbene arm. Mitigation: lipid panel if using combination products ([Dellinger et al., 2017](https://pubmed.ncbi.nlm.nih.gov/29184669/)).  

- **Methyl donors (trimethylglycine, folate, methylcobalamin):** Caution. Low folate, B12, or betaine can let high-dose nicotinamide clearance raise homocysteine. Mitigation: replete methyl donors if homocysteine rises at high nicotinamide riboside doses.  

- **Levodopa (and other Parkinson medications):** Monitor. Apparent motor improvement or worsening can track time since levodopa rather than nicotinamide riboside, misstating clinical change. Mitigation: keep dosing clocks constant ([Berven et al., 2023](https://pubmed.ncbi.nlm.nih.gov/38016950/)).  

- **Cytotoxic chemotherapy (cisplatin, paclitaxel, doxorubicin):** Caution. Neuropathy-prevention trials exist, while mouse work raises a tumor-fuel concern. Mitigation: oncology oversight; several protocols exclude active cancer.  

- **OTC (over-the-counter) high-dose vitamin B3 multi-ingredient NAD-precursor products:** Caution. Hidden nicotinamide or nicotinic acid can push total B3 above studied nicotinamide riboside-only intakes. Mitigation: read labels and do not combine multiple vitamin B3 products.  

**Populations who should avoid Nicotinamide Riboside:**  

- Active neoplastic malignancy (other than treated non-melanoma skin cancer), including disease within ~2 years, given mouse metastasis data and common trial exclusions  
- Pregnancy and lactation, because human safety data are insufficient (European Food Safety Authority novel-food opinions)  
- Children, outside a supervised deficiency or rare-disease protocol  
- Known hypersensitivity to nicotinamide riboside or capsule excipients  


  
## Risk Mitigation Strategies

- **Stay in studied oral dose bands:** Most longevity-oriented protocols use 300–1,000 mg/day; 3,000 mg/day has only 4-week Parkinson disease safety data, which limits homocysteine and unknown risks.  

- **Split higher intakes:** Twice-daily 500 mg capsules match the short nucleoside half-life and are used to blunt peak-related gastrointestinal symptoms in the Martens and Airhart regimens.  

- **Watch methylation at high dose:** Homocysteine plus folate/B12 at baseline and after 4 weeks when intake is ≥1,000–3,000 mg/day addresses NNMT-related methyl draw.  

- **Screen for active cancer:** Mouse metastasis data and trial exclusions make a recent-malignancy history a protocol exclusion rather than an unsupervised start.  

- **Prefer nicotinamide riboside-only if lipids are a concern:** Combination pterostilbene products carried the LDL signal; nicotinamide riboside-only trials did not.  

- **Third-party tested chloride salt:** Counterfeit Tru Niagen and under-dosed products are documented; tested Niagen chloride reduces the risk of taking a mislabeled dose.  


  
## Therapeutic Protocol

- **ChromaDex / Seals–Martens clinical band:** 500 mg twice daily (1,000 mg/day) of Niagen nicotinamide riboside chloride for 6 weeks raised blood-cell NAD+ ~60% in middle-aged and older adults ([Martens et al., 2018](https://pubmed.ncbi.nlm.nih.gov/29599478/)).  

- **Consumer Niagen label:** Tru Niagen marketing commonly uses 300 mg once daily; Conze showed dose-dependent NAD+ (+22%, +51%, +142% at 100, 300, and 1,000 mg) ([Conze et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31278280/)).  

- **Elysium Basis combination:** Nicotinamide riboside plus pterostilbene is an alternative used in older adults; LDL rose at double dose, so it is not interchangeable with nicotinamide riboside-only ([Dellinger et al., 2017](https://pubmed.ncbi.nlm.nih.gov/29184669/)).  

- **Tzoulis / Haukeland neurodegeneration band:** 1,000 mg/day (NADPARK) to 1,500 mg twice daily (NR-SAFE) in Parkinson disease; a 2-year Alzheimer trial uses 1,000 mg twice daily ([Brakedal et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35235774/)).  

- **Huberman personal protocol:** 500 mg nicotinamide riboside in the morning, often combined with nicotinamide mononucleotide; presented as a personal energy protocol, not a lifespan claim.  

- **Attia posture:** NAD-precursor use is treated as unproven for lifespan; not framed as a default longevity drug in his NAD review.  

- **Time of day:** Morning or morning-plus-evening is typical; NAD+ follows a circadian rhythm, and late dosing is sometimes avoided when sleep is sensitive.  

- **Half-life and splitting:** Apparent plasma half-life of the parent nucleoside is about 2–3 hours; NAD+ remains up with daily dosing, so split doses are used at ≥1,000 mg/day ([Airhart et al., 2017](https://pubmed.ncbi.nlm.nih.gov/29211728/)).  

- **Genetics:** NMRK1/NMRK2, NAMPT, CD38, and NNMT could change response; no clinical genotype-based nicotinamide riboside dose exists.  

- **Sex and age:** No sex-specific milligram rule. Older adults are the main studied group; metabolic nulls in obese men caution against assuming insulin-sensitizing effects.  

- **Baseline NAD+ and disease:** Lower baseline NAD+ predicted a larger rise in Martens; PAD, Parkinson disease, and COPD are the conditions with the most clinical-signal papers.  


  
## Discontinuation & Cycling

- **Duration:** Not a deficiency vitamin for well-nourished adults; used as an ongoing longevity experiment rather than a required lifelong drug.  

- **Washout:** Whole-blood NAD+ had returned to baseline 12 weeks after stopping in the COPD trial, showing the biochemical effect is reversible ([Norheim et al., 2024](https://pubmed.ncbi.nlm.nih.gov/39548320/)).  

- **Withdrawal:** No nicotinamide riboside withdrawal syndrome is described in randomized trials; stopping is usually abrupt.  

- **Taper:** No taper is used in published protocols; plasma nucleoside is already short-lived.  

- **Cycling:** No evidence that time off preserves efficacy; NAD+ engagement tracks ongoing intake, not a rebound that cycling would prevent.  


  
## Sourcing and Quality

- **Niagen chloride:** Most trials use ChromaDex nicotinamide riboside chloride (Niagen / Tru Niagen), the GRAS crystalline salt; labels that state milligrams of nicotinamide riboside, not only salt weight, allow dose comparison.  

- **Third-party testing:** NSF International or United States Pharmacopeia testing matters because ConsumerLab has reported counterfeit Tru Niagen and products far below claimed nicotinamide riboside.  

- **Salt form:** Chloride versus hydrogen malate changes the nicotinamide riboside fraction of a milligram dose; comparing products on elemental nicotinamide riboside avoids under-dosing.  

- **Combination products:** Basis-type formulas add pterostilbene and are a different evidence object, including the LDL signal.  

- **Reputable supply:** Trial-aligned brands that disclose Niagen as the source reduce the risk of substituting undeclared nicotinamide or empty capsules.  


  
## Practical Considerations

- **Time to effect:** Whole-blood NAD+ rises within 2 weeks and plateaus; PAD walk-distance was measured at 6 months; Parkinson scores moved over 4 weeks; insulin-sensitivity trials were null at 6–12 weeks.  

- **Common pitfalls:** Expecting weight loss or clamp-proven insulin sensitization; combining several NAD-precursor products; treating NAD+ blood tests as a longevity outcome; buying untested capsules after counterfeit reports.  

- **Regulatory status:** Dietary supplement in the United States, not a U.S. Food and Drug Administration-approved drug to treat disease; nicotinamide riboside chloride is GRAS and an EU novel food. Disease claims remain off-label marketing.  

- **Cost:** Consumer 300 mg/day is typically tens of U.S. dollars per month; 1,000 mg/day costs more. Intravenous NAD clinics have a revenue incentive to prefer infusions over oral precursors; those infusions are not this intervention.  


  
## Interaction with Foundational Habits

- **Sleep:** Indirect. NAD+ participates in circadian clocks. Huberman has reported no sleep disruption on morning nicotinamide riboside; late dosing is sometimes avoided on anecdotal insomnia grounds. No polysomnography benefit is established.  

- **Nutrition:** Direct on one-carbon metabolism (the folate/methylation cycle). High nicotinamide clearance uses methyl groups; folate, B12, and trimethylglycine sit on that path. Food nicotinamide riboside in milk is trivial next to supplement milligrams. Not a pellagra (niacin-deficiency disease) therapy in place of mixed niacin equivalents.  

- **Exercise:** None in healthy muscle; direct in PAD. PAD walking improved without added resveratrol; healthy-adult maximal oxygen uptake and strength generally did not. A 2025 hypertension pilot found no extra daytime blood-pressure drop when nicotinamide riboside was layered onto walking. Rodent work has raised a possible training-adaptation blunt; human performance data are mixed-to-null.  

- **Stress management:** Indirect. Elhassan reported lower circulating cytokines, a possible overlap with inflammatory stress biology; no trial shows a cortisol or perceived-stress benefit. Sirtuin effects on stress-response genes remain mechanistic.  


  
## Monitoring Protocol & Defining Success

Baseline testing in nicotinamide riboside trials typically includes a metabolic panel, blood counts, lipids, seated blood pressure, and, where available, whole-blood NAD+. Homocysteine and B-vitamin status are added when high doses are planned because nicotinamide clearance consumes methyl groups. Practices oriented to function sometimes add high-sensitivity C-reactive protein and a walking or cognitive baseline if those are the intended outcomes.  

Ongoing labs in published protocols are sparse. Conze resampled NAD+ at 2 and 8 weeks, Martens at 6 weeks, and Norheim at 6 weeks then 12 weeks after stopping. Longevity clinics often repeat NAD+ at 4 weeks, then every 3–6 months with homocysteine, liver enzymes, and blood pressure. NAD+ is not a validated clinical surrogate; it documents target engagement. Success is a sustained NAD+ rise without homocysteine or liver-enzyme drift, plus a pre-specified function such as 6-minute walk rather than a laboratory number alone.  

| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|---|---|---|---|
| Whole-blood NAD+ | No established functional target; track change from personal baseline (trials often ~50–140% rise at 300–1,000 mg/day) | Confirms target engagement | Fasting; last dose 12–14 h prior in some protocols; not a validated clinical surrogate |
| Homocysteine | <8 µmol/L | Methylation drain from nicotinamide clearance | Functional target <8 µmol/L; conventional often <15 µmol/L; fasting; pair with folate, B12, B6 |
| hs-CRP | <1.0 mg/L | Systemic inflammation | high-sensitivity C-reactive protein; functional <1.0 mg/L vs conventional often <3.0 mg/L; fasting not required |
| AST / ALT | <30 U/L | Hepatic tolerance | aspartate and alanine aminotransferase; functional <30 U/L vs conventional often <40 U/L; fasting optional |
| Systolic / diastolic blood pressure | <120/80 mmHg | Vascular response | Morning, seated, repeated |
| eGFR | >90 mL/min/1.73 m² when attainable; otherwise track slope | Renal handling of NAD catabolites | Functional >90 vs conventional often ≥60 mL/min/1.73 m²; especially if CKD |
| LDL cholesterol | Functional often <70–100 mg/dL depending on risk | Combination-product lipid signal | Fasting; more relevant with pterostilbene combos; conventional often <100–130 mg/dL |

Qualitative markers used alongside labs:  

- Walking capacity or claudication (leg pain on walking from limited arterial flow) distance in PAD  
- Daytime energy and recovery, interpreted cautiously because of placebo effects  
- Motor-symptom stability in Parkinson disease, with medication timing held constant  
- Sleep continuity if dosing is moved later in the day  
- Gastrointestinal comfort during the first 2 weeks  


  
## Emerging Research

- **N-AD Alzheimer outcome trial:** [NCT07741071](https://clinicaltrials.gov/study/NCT07741071) is a recruiting 270-person, 2-year, phase 2 trial of 1,000 mg twice daily versus placebo, with Clinical Dementia Rating sum of boxes as the primary endpoint (Haukeland University Hospital). A positive or null result would move nicotinamide riboside out of biomarker-only dementia claims.  

- **NICE-PAD II:** [NCT07782671](https://clinicaltrials.gov/study/NCT07782671) is a not-yet-recruiting 250-person phase 3 walk-distance trial (1,000 mg/day, 6 months) designed to confirm or refute the 2024 PAD finding ([McDermott et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38871717/)).  

- **Neurovascular coupling in aging:** [NCT05483465](https://clinicaltrials.gov/study/NCT05483465) is a recruiting 214-person, 8-week, 1,000 mg/day trial of brain blood-flow responses in adults 60–85 years (University of Oklahoma; Elysium collaborator). A null vascular result would weaken the Martens blood-pressure story.  

- **Atherosclerosis signal in mice:** Nicotinamide riboside increased atherosclerotic plaques and inflammation in Apoe-knockout mice, a finding that cuts against vascular-benefit claims and needs human plaque data ([Wang et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40215896/)).  

- **Company-funded evidence base:** The Gallagher PRISMA review still finds inconclusive healthspan effects despite clear NAD+ engagement; longer independent trials are the main way that commercial bias in the current literature could be tested ([Gallagher & Emmanuel, 2026](https://pubmed.ncbi.nlm.nih.gov/41655607/)).  


  
## Conclusion

Nicotinamide riboside is an oral vitamin B3 relative that reliably raises the blood pool of a cellular energy coenzyme. For a health- and longevity-oriented adult, that biochemical signal is the firmest finding. A six-month walking trial in peripheral artery disease and small Parkinson disease studies supply the main clinical hints; they remain limited in size and duration. Blood-pressure and metabolic stories from mice did not hold as a consistent human result. Muscle mass, insulin response, and thinking scores in older adults have not improved in pooled or dedicated trials.  

Safety over weeks to a few months is generally favorable, with mild stomach symptoms the most repeated complaint and no replicated serious harm at studied doses. Open questions sit beside that record: a possible small rise in a methylation-related blood marker at very high intake, mouse work linking the nutrient to tumor spread, and the fact that companies that sell branded nicotinamide riboside fund a large share of the human studies. Those conflicts do not erase the blood coenzyme data, but they do color how strongly clinical claims can be read.  

Taken together, nicotinamide riboside is a well-characterized way to move a longevity-related coenzyme, with a narrow set of early clinical signals and a still-unproven case for extending healthy human life.  

**[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**